mRNA-1273 shows greater COVID-19 protection than NVX-CoV2705 in retrospective US cohort study
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider mRNA-1273's greater observed effectiveness versus NVX-CoV2705 in retrospective data, but note study limitations.
This retrospective matched cohort study analyzed data from a large US claims database, comparing COVID-19 outcomes in 69,140 mRNA-1273 recipients and 34,570 NVX-CoV2705 recipients who were matched on demographic and clinical factors. The population consisted of US insured adults aged 18 years or older, with follow-up from day 7 after vaccination through up to 180 days.
For the primary outcome of medically-attended COVID-19, mRNA-1273 showed an adjusted comparative vaccine effectiveness (cVE) of 31.7% (95% CI 23.4% to 39.1%) compared to NVX-CoV2705, with 706 events (1.02%) in mRNA-1273 recipients versus 512 events (1.48%) in NVX-CoV2705 recipients. For hospitalization with COVID-19, the adjusted cVE was 40.7% (95% CI 13.5% to 59.4%), with 61 events (0.09%) in mRNA-1273 recipients and 49 events (0.14%) in NVX-CoV2705 recipients. In recipients aged 65 years or older, adjusted cVE was 25.7% for medically-attended COVID-19 and 41.7% for hospitalization.
Safety and tolerability data were not reported in this analysis. Key limitations include the observational design, which cannot establish causality, potential residual confounding despite matching, reliance on claims data for outcome ascertainment, and lack of information on prior infection status or variant exposure. The study was conducted in a US insured population, which may limit generalizability.
For clinical practice, these findings suggest a potential effectiveness difference between these vaccine platforms in real-world use, but the retrospective nature and absence of safety data warrant cautious interpretation. The results may inform vaccine selection discussions while awaiting prospective comparative data.
More on COVID
Review of RISE-mitigation strategies in Ghana shows high immunization coverage and improved oxygen access
Ghana reduced oxygen travel distances and improved vaccine coverage with new pandemic strategies
This review uses mixed qualitative and quantitative approaches to evaluate RISE-mitigation strategies in Ghana. The analysis covers 10 novel…
New strategies in Ghana helped get oxygen closer to patients and reached 93% of people with vaccines while treating most confirmed cases.
Narrative review on COVID-19 and gut microbiome disruption and immune effects
Microbiome disruption may link SARS-CoV-2 to long-term health issues
This narrative review synthesizes evidence on COVID-19 and the intestinal microbiome. It finds SARS-CoV-2 infection can induce dysbiosis and…
A review suggests the virus may alter gut bacteria, immune signals, and brain health, highlighting a need for One Health pandemic preparedne…
Speleotherapy improves asthma control and breathing patterns in patients with respiratory conditions
Speleotherapy improves breathing patterns and symptoms for asthma, COPD, and Long COVID patients
A randomized trial of 208 patients across Germany, Austria, and Italy found that a three-week speleotherapy course enhanced asthma control a…
A three-week course in mineral-rich caves helped people with asthma, COPD, or Long COVID breathe easier and feel better, though lung functio…
Systematic review and meta-analysis links COVID-19 infection to 41% higher new-onset diabetes risk
Meta-analysis links COVID-19 infection to higher new-onset diabetes risk
This systematic review and meta-analysis evaluated sixteen studies comparing COVID-19 survivors with non-infected individuals. The pooled an…
A meta-analysis of sixteen studies suggests COVID-19 infection is associated with a 41% increased risk of developing new-onset diabetes at l…
View Original Abstract ↓
Background: COVID vaccination with periodically updated compositions remains important as SARS-CoV-2 continues to circulate, cause disease, and evolve. Available COVID-19 vaccines in the 2024-2025 season differed by platform, including mRNA-1273, an mRNA-based vaccine, and NVX-CoV2705, a recombinant protein-based vaccine and antigen composition (KP.2-targeted and JN.1-targeted, respectively). There is limited head-to-head real-world evidence comparing the effectiveness of these different approaches to prevention of severe outcomes with COVID-19. We compared mRNA-1273 with protein-based NVX-CoV2705 in insured US adults vaccinated during the 2024-2025 season. Methods: We conducted a retrospective matched cohort study in a large US claims database. Adults aged 18 years or older who received mRNA-1273 or NVX-CoV2705 between Aug 31, 2024 and Feb 28, 2025 were eligible. Recipients were exactly matched 2:1 on key demographic and clinical factors and then weighted with stabilized inverse probability of treatment weights. Outcomes were medically-attended COVID-19 and hospitalization with COVID-19 from day 7 after vaccination through up to 180 days of follow-up. We calculated comparative vaccine effectiveness (cVE) as 100 x (1-- hazard ratio). Results: Of 858,138 eligible mRNA-1273 recipients and 34,667 eligible NVX-CoV2705 recipients, 69,140 and 34,570, respectively, entered the matched cohort. Median (Q1, Q3) follow-up was 180 (163, 180) days for mRNA-1273 and 180 (162,180) for NVX-CoV2705. Medically attended COVID-19 occurred in 706 (1.02%) mRNA-1273 recipients and 512 (1.48%) NVX-CoV2705 recipients; adjusted cVE (95% CI) was 31.7% (23.4%, 39.1%). Hospitalization with COVID-19 occurred in 61 (0.09%) and 49 (0.14%) recipients, respectively; adjusted cVE (95% CI) was 40.7% (13.5%, 59.4%). In the 47,754 mRNA-1273 recipients matched to 23,877 NVX-CoV2705 recipients aged [≥]65, adjusted cVE (95% CI) was 25.7% (15.4%, 34.8%) against medically-attended COVID-19 and 41.7% (14.3%, 60.4%) against hospitalization with COVID-19. Conclusions: In this insured US adult population, mRNA-1273 demonstrated greater effectiveness against medically attended COVID-19 and hospitalization with COVID-19 than the protein-based NVX-CoV2705. These findings highlight the potential public-health importance of considering vaccine platform and variant selection when planning for upcoming seasons.
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
Related in Infectious Disease
Pooled cytomegalovirus retinitis prevalence is 3% among people with HIV in sub-Saharan Africa
Cytomegalovirus retinitis risk varies across sub-Saharan Africa regions
This systematic review and meta-analysis synthesized data from 1931 people living with HIV in sub-Saharan Africa. The pooled prevalence of c…
A meta-analysis found that cytomegalovirus retinitis prevalence in people living with HIV ranges from less than 1% to 7% depending on the re…
Biofeedback therapy improves constipation response rates and symptom scores in adults compared to control groups
Biofeedback therapy helps more adults with chronic constipation than usual care
A meta-analysis of 19 trials shows biofeedback therapy significantly boosts response rates and bowel frequency for chronic constipation. Whi…
Biofeedback therapy significantly improved bowel movement frequency and quality of life for adults with chronic constipation, though study l…
Microbiome research in GCC countries is uneven, observational, and lacks One Health integration
GCC microbiome research is growing but needs a unified regional plan to help people
This systematic review of 110 studies on microbiome research in GCC countries found most publications were observational and focused on huma…
A review of 110 studies shows the Gulf region is active in microbiome science, yet uneven progress and a lack of One Health approaches hold …
MESNA-assisted surgery disrupts disease-associated microbiota equilibrium in paediatric cholesteatomatous chronic otitis media
Early data suggest MESNA may help restore ear bacteria in children with chronic ear infections
This observational review characterizes the microbiota of paediatric patients with cholesteatomatous chronic otitis media (CCOM) and evaluat…
A small review links MESNA-assisted surgery to changes in ear bacteria, offering hope for preventing infection return in children.
From Other Specialties
Probiotics, synbiotics, and berberine modestly lower fasting glucose and HbA1c in type 2 diabetes
Probiotics and Berberine Modestly Lower Blood Sugar in Type 2 Diabetes
This meta-analysis of over 2,000 participants found that probiotics, synbiotics, and berberine produced significant but modest reductions in…
Probiotics, synbiotics, and berberine may help lower blood sugar and HbA1c, but the effects are modest.
High-dose ocrelizumab 1200/1800 mg shows no significant difference in disability progression versus 600 mg in MS
High-dose ocrelizumab did not further reduce disability progression in multiple sclerosis patients
This phase 3b randomized controlled trial in 860 and 753 patients with relapsing or primary progressive multiple sclerosis found that high-d…
A large trial found that higher doses of ocrelizumab did not lower the risk of disability progression compared to the standard dose in multi…
Ocrelizumab reduces disability progression risk in primary progressive multiple sclerosis versus placebo
Ocrelizumab reduces disability risk for primary progressive multiple sclerosis patients
This phase 3b trial evaluated intravenous ocrelizumab versus placebo in patients with primary progressive multiple sclerosis. The study foun…
A large trial found ocrelizumab significantly lowers the risk of disability progression in patients with primary progressive multiple sclero…
Prasinezumab showed non-significant delay in motor progression versus placebo in early-stage Parkinson's disease
Early Parkinson's drug trial shows no delay in motor progression
This phase 2b trial evaluated intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable medication. The study f…
A Phase 2b trial of prasinezumab in early Parkinson's disease failed to meet its primary endpoint of delaying motor progression compared to …